Veterinary Pain Management - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The veterinary pain management market size was valued at USD 1.75 billion in 2025 and estimated to grow from USD 1.85 billion in 2026 to reach USD 2.46 billion by 2031, at a CAGR of 5.84% during the forecast period (2026-2031). This report is Segmented by Product (Drugs Including NSAIDs, Opioids, Local Anesthetics, and More; Devices Including Laser Therapy, Electromagnetic Therapy), Animal Type (Companion Animals, Livestock), End User (Veterinary Hospitals & Clinics, Homecare Settings, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Veterinary Pain Management Market Trends and Insights

Rising Pet Ownership & Humanization

Pet owners increasingly expect human-level clinical standards, prompting premium adoption of innovations such as Zoetis’ bedinvetmab injections. The American Animal Hospital Association’s 2024 guidelines codify multimodal regimens, legitimizing antibody use alongside NSAIDs. Retailers of welfare-certified livestock products likewise seek credible analgesia claims to justify price premiums, widening overall demand.

Growing Osteoarthritis & Post-Operative Pain Incidence

Osteoarthritis affects 20% of dogs older than one year and nearly 90% of cats above 12 years. FDA approval of bedinvetmab established biologics as viable long-term solutions, with trial success rates of 43.5% versus 16.9% for placebo. Long-acting bupivacaine formulations such as Elanco’s Nocita deliver 72-hour coverage, curbing readmission rates and owner burden. Productivity losses in untreated livestock further amplify the economic argument for effective analgesia.

Adverse-Event Profile of NSAIDs & Opioids

Veterinarians weigh renal, hepatic, and gastrointestinal risks when prescribing NSAIDs, and diversion concerns complicate opioid dispensing. Post-marketing surveillance of bedinvetmab documented 17,162 adverse reports from 18 million doses, reminding clinicians that even innovative biologics carry safety obligations. FDA approval of suzetrigine for human use underscores momentum toward non-opioid classes that may cross into veterinary care.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Livestock Welfare Regulations
• Mandatory Multimodal Analgesia Protocols (EU, US)
• Stringent Regulatory Approval Timelines

Segment Analysis

The pharmaceutical segment captured 81.05% of the veterinary pain management market size in 2025, anchored by NSAIDs such as meloxicam, yet device revenues are growing at a 6.03% CAGR. NSAIDs persist as first-line therapy because of cost efficiency, whereas opioid use retreats under diversion scrutiny. Long-acting local anesthetics like Nocita extend analgesia to 72 hours and mitigate readmission. Alpha-2 agonists retain niche roles in large animal sedation. Early cannabinoid entrants address chronic pain that resists conventional classes, despite regulatory headwinds.

Portable diode-laser units, PEMF mats, and shockwave systems are carving out space as stand-alone or adjunct solutions. Clinics promote these technologies for geriatric pets intolerant of NSAIDs, while equine practitioners leverage PEMF for musculoskeletal recovery. Manufacturers now bundle software analytics that log session parameters, enabling veterinarians to document compliance with multimodal mandates. The device trajectory signals that the veterinary pain management market will increasingly balance pharmacology with non-pharmacologic modalities.

Complete Report Scope:

• By Product (Value)
  • Drugs
    • NSAIDs
    • Opioids
    • Local Anesthetics
    • Alpha-2 Agonists
    • Cannabinoid-based Therapeutics
  • Devices
    • Laser Therapy
    • Electromagnetic Therapy
• By Animal Type (Value)
  • Companion Animals
  • Livestock
• By End User (Value)
  • Veterinary Hospitals & Clinics
  • Homecare Settings
  • Academic & Research Institutes
• By Region (Value)
  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa

Geography Analysis

North America contributed 41.78% of global revenue in 2025, underpinned by high pet insurance penetration and a regulatory climate that enables rapid first-to-market approvals. Monoclonal antibody pioneers capitalized on FDA review efficiencies, securing early brand recognition. Canada’s cautious stance on controlled substances has, however, catalyzed investment in non-opioid drugs and cannabinoid research pipelines.

Europe follows closely, shaped by some of the world’s strictest welfare legislation. Mandatory multimodal analgesia elevates demand for diverse product kits, pushing suppliers to hold broader formularies. Antimicrobial stewardship programs restrain NSAID courses, indirectly prompting uptake of laser and electromagnetic therapy devices. The United Kingdom’s post-Brexit regulatory autonomy is allowing accelerated pathways for niche products, giving smaller firms an entry door ahead of pan-EU approvals.

Asia-Pacific is the fastest-expanding region with a projected 7.18% CAGR. Urban pet ownership in China rose sharply after pandemic-era lifestyle shifts, while Japan’s aging pet cohort parallels that of Western markets. South Korea’s reform of its Animal Protection Act stipulates pain relief during cosmetic surgery and disease treatment, creating new baseline demand. Emerging Southeast Asian economies deploy welfare upgrades to align with export certification criteria, translating policy into accessible market volume for globally established brands.

List of Companies Covered in this Report:

• Zoetis
• Boehringer Ingelheim
• Elanco Animal Health Inc.
• Merck & Co., Inc. (Animal Health)
• Dechra Pharmaceuticals
• Ceva Santé Animale SAS
• Virbac S.A.
• Vetoquinol
• Norbrook Laboratories Ltd
• Chanelle Pharma Group
• Orion
• Parnell Pharmaceuticals Holdings Ltd
• Assisi Animal Health LLC
• LiteCure LLC (Companion Animal Health)
• PulseVet Technologies Inc.
• Zomedica Corp.
• PetVivo Holdings Inc.
• Ellevet Sciences LLC
• Animalcare Group plc
• Alivira Animal Health Ltd

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support